Solid Deferred Long Term Liab vs Total Stockholder Equity Analysis
SLDB Stock | USD 10.25 0.17 1.63% |
Solid Biosciences financial indicator trend analysis is much more than just breaking down Solid Biosciences LLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Solid Biosciences LLC is a good investment. Please check the relationship between Solid Biosciences Deferred Long Term Liab and its Total Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Deferred Long Term Liab vs Total Stockholder Equity
Deferred Long Term Liab vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Solid Biosciences LLC Deferred Long Term Liab account and Total Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Solid Biosciences' Deferred Long Term Liab and Total Stockholder Equity is 0.83. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Solid Biosciences LLC, assuming nothing else is changed. The correlation between historical values of Solid Biosciences' Deferred Long Term Liab and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Solid Biosciences LLC are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Deferred Long Term Liab i.e., Solid Biosciences' Deferred Long Term Liab and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.83 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Solid Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Solid Biosciences LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. The current year's Issuance Of Capital Stock is expected to grow to about 79.7 M, whereas Selling General Administrative is forecasted to decline to about 20.8 M.
Solid Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Solid Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Solid Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 103.5M | 171.2M | 232.4M | 260.3M | 164.9M | 152.1M | |
Other Current Liab | 52K | 8.6M | 9.6M | 16.7M | 10.2M | 8.4M | |
Total Current Liabilities | 18.3M | 24.5M | 23.6M | 22.5M | 14.5M | 18.1M | |
Total Stockholder Equity | 80.0M | 132.1M | 208.2M | 211.7M | 126.5M | 82.2M | |
Net Tangible Assets | 80.0M | 132.1M | 208.2M | 211.7M | 243.4M | 255.6M | |
Net Debt | (69.0M) | (149.6M) | (117.1M) | (126.8M) | (47.8M) | (50.1M) | |
Retained Earnings | (316.3M) | (404.6M) | (476.8M) | (562.7M) | (658.8M) | (625.8M) | |
Accounts Payable | 7.1M | 3.3M | 4.5M | 3.2M | 2.0M | 4.0M | |
Cash | 76.0M | 154.7M | 119.1M | 155.4M | 74.0M | 92.2M | |
Cash And Short Term Investments | 83.5M | 154.7M | 207.8M | 213.7M | 123.6M | 130.5M | |
Common Stock Total Equity | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Common Stock Shares Outstanding | 2.7M | 3.5M | 7.1M | 8.5M | 19.9M | 20.9M | |
Short Term Investments | 7.5M | 0.0 | 88.6M | 58.3M | 49.6M | 38.4M | |
Liabilities And Stockholders Equity | 103.5M | 171.2M | 232.4M | 260.3M | 164.9M | 152.1M | |
Non Current Liabilities Total | 5.1M | 14.6M | 568K | 26.1M | 23.9M | 29.3M | |
Other Current Assets | 1.5M | 1.5M | 8.7M | 5.9M | 6.1M | 3.2M | |
Other Stockholder Equity | 396.3M | 536.6M | 684.9M | 774.5M | 785.2M | 411.0M | |
Total Liab | 23.4M | 39.1M | 24.2M | 48.6M | 38.5M | 42.5M | |
Total Current Assets | 86.3M | 158.9M | 222.6M | 219.6M | 129.7M | 135.9M | |
Accumulated Other Comprehensive Income | 1K | 0.0 | (45K) | (68K) | 15K | 15.8K | |
Common Stock | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Property Plant And Equipment Net | 16.6M | 11.7M | 7.6M | 38.6M | 33.2M | 16.6M | |
Non Current Assets Total | 17.2M | 12.3M | 9.8M | 40.6M | 35.2M | 18.2M | |
Non Currrent Assets Other | 3.1M | 536K | 209K | 94.0K | 175K | 198.6K | |
Property Plant And Equipment Gross | 16.6M | 11.7M | 19.3M | 49.6M | 45.9M | 48.2M | |
Non Current Liabilities Other | 5.1M | 1.3M | 568K | 26.1M | 30.0M | 31.5M | |
Property Plant Equipment | 16.6M | 11.7M | 6.5M | 9.7M | 11.1M | 9.1M | |
Net Invested Capital | 80.0M | 132.1M | 208.2M | 211.7M | 126.5M | 129.6M | |
Net Working Capital | 68.0M | 134.4M | 199.0M | 197.1M | 115.2M | 139.8M | |
Short Long Term Debt Total | 7.1M | 5.2M | 2.1M | 28.5M | 26.3M | 27.6M | |
Capital Surpluse | 396.3M | 536.6M | 684.9M | 774.5M | 890.6M | 597.6M | |
Capital Lease Obligations | 7.1M | 5.2M | 2.1M | 28.5M | 26.3M | 27.6M | |
Capital Stock | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Short Term Debt | 1.9M | 2.2M | 1.5M | 2.6M | 2.3M | 2.0M |
Currently Active Assets on Macroaxis
When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Solid Biosciences LLC information on this page should be used as a complementary analysis to other Solid Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
CEOs Directory Screen CEOs from public companies around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Solid Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.83) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.57) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.